| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
See Remarks
1 company
Matthew R Henn is See Remarks at MCRB. Matthew R Henn's net worth is not public. Form 4 filings only show shares in the companies where this person is an insider; those holdings are worth an estimated $16K at current prices.
Our model assigns Matthew R Henn a middling insider score of 69/100, based on 12 past trades. Over a 12-month horizon, 66.7% of those trades were profitable, with an average 12-month return of +15.0%.
The MCRB filings lean toward selling, a net 112,200 shares.
Matthew R Henn has 26 Form 4 filings on record from January 2020 to August 2026, all as Seres Therapeutics (MCRB), 2020–2026.
The 54 reported transactions were 22 option exercises, 16 open-market sales, 15 option or other derivative awards and 1 stock award.
Counted by filing, the open-market trades come to no purchases and 14 sales worth about $2.5M.
The largest open-market sale was 91,812 shares of MCRB at an average $27.04 on December 1, 2020, about $2.5M.
All 13 sales since April 2023 were made under a Rule 10b5-1 trading plan, set up in advance.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Aug 17, 2026 | MCRB Seres Therapeutics, Inc. | See Remarks | Sale+OE10b5-1 | 81 | $4.55 | $368.55 | -1.0% | - | - | |
| May 18, 2026 | MCRB Seres Therapeutics, Inc. | See Remarks | Sale+OE10b5-1 | 77 | $7.53 | $579.81 | -1.0% | -40.6% | - | |
| Feb 15, 2026 | MCRB Seres Therapeutics, Inc. | See Remarks | Sale+OE10b5-1 | 89 | $8.47 | $753.83 | -1.1% | -7.7% | - | |
| Nov 15, 2025 | MCRB Seres Therapeutics, Inc. | See Remarks | Sale+OE10b5-1 | 1,257 | $17.30 | $21,746.10 | -14.3% | -49.2% | - | |
| Aug 18, 2025 | MCRB Seres Therapeutics, Inc. | See Remarks | Sale+OE10b5-1 | 73 | $16.65 | $1,215.45 | -1.6% | +22.3% | -75.5% | |
| May 16, 2025 | MCRB Seres Therapeutics, Inc. | See Remarks | Sale+OE10b5-1 | 77 | $7.28 | $560.56 | -1.7% | +126.0% | +2.4% | |
| Feb 18, 2025 | MCRB Seres Therapeutics, Inc. | See Remarks | Sale+OE10b5-1 | 3,953 | $0.81 | $3,203.51 | -4.5% | -52.0% | -50.5% | |
| Nov 18, 2024 | MCRB Seres Therapeutics, Inc. | See Remarks | Sale+OE10b5-1 | 927 | $0.54 | $501.23 | -1.2% | +43.6% | +113.4% | |
| Oct 28, 2024 | MCRB Seres Therapeutics, Inc. | See Remarks | Sale+OE10b5-1 | 3,984 | $0.69 | $2,749.36 | -5.0% | +20.2% | +22.6% | |
| Aug 16, 2024 | MCRB Seres Therapeutics, Inc. | See Remarks | Sale+OE10b5-1 | 923 | $0.84 | $775.32 | -1.4% | -32.7% | -5.1% |